Scholl Hendrik Peter
Chief Medical Officer
Scholl Hendrik Peter has filed 2 SEC Form 4 filings (13 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 22, 2026.
On the most recent filing, Scholl Hendrik Peter is listed as Chief Medical Officer at BELITE BIO, INC. Inside the rolling window, Scholl Hendrik Peter reported no open-market purchases and 2 open-market sales totaling $2.9M in BLTE. The largest disclosed transaction in the window is a sale of 10,000 BLTE shares on Jun 18, 2026, worth $1.5M.
Companies traded
Other insiders at BLTE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Scholl Hendrik Peter made?
Scholl Hendrik Peter has filed 2 SEC Form 4 filings (13 transaction rows) across 1 company since 2026.
Which companies does Scholl Hendrik Peter trade?
Scholl Hendrik Peter has filed SEC Form 4 disclosures for 1 company, including BLTE.
When was Scholl Hendrik Peter's most recent SEC Form 4 filing?
Scholl Hendrik Peter's most recent SEC Form 4 filing on Tracefour is dated Jun 22, 2026.
What is Scholl Hendrik Peter's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Scholl Hendrik Peter is listed as Chief Medical Officer.
What is Scholl Hendrik Peter's total buy and sell value in the current window?
Inside the rolling retention window, Scholl Hendrik Peter bought $0 and sold $2.9M based on SEC Form 4 filings.
What was Scholl Hendrik Peter's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,000 BLTE shares on 2026-06-18, worth $1.5M, per SEC Form 4 filings.